Literature DB >> 16379616

Relationship of stage mensuration data to the performance of new and used cascade impactors.

Daryl L Roberts1, Francisco J Romay.   

Abstract

Cascade impaction is a standard test method for characterizing the quality of inhalable drug products. The sizes of the nozzles on each stage of the impactor are the critical dimensions for the performance of the impactor. Compendial reference methods call for periodic measurement of the size of the nozzles on each stage, a procedure known as stage mensuration. There is however currently no guidance on acceptable mensuration criteria. We aim to remedy this situation by providing a sound basis for understanding and using mensuration data, be it for acceptance criteria for new impactors or for the setting of mensuration tolerances for in-use impactors. We first show that multi-nozzle impactor stages behave as if all of the nozzles are equal in size to an effective diameter, , that is composed of the area-mean and areamedian diameters, W* and , calculated directly from the individual nozzle diameters for all nozzles on a given stage (equation 1): W= (W*)(2/3) x (W)(1/3) (1). Hence, the effective diameter provides an intuitive and technically sound basis for setting acceptance criteria for new and in-use impactors. We tabulate these criteria for the Mark II eight-stage Andersen cascade impactor and the Next Generation Pharmaceutical Impactor in a manner similar to the tables of critical impactor dimensions published in EP Supplement 5.1 and in USP 28. For two different impactors or for one impactor measured at two different times (e.g., at manufacture and in use), we find that the D50 values of a given stage are related to the effective diameters by D(50,2)/D(50,1)= (W(2)/W(1))(3/2) (2). Using the stage mensuration data for new, as-manufactured NGIs, we compare the D(50 )values of the first 125 as-manufactured NGIs with those of the archivally calibrated NGI. We further establish that the archivally calibrated NGI has D(50) values within 0.3% of an entirely perfect, hypothetical NGI with all nozzles equal to the nominal nozzle diameters. We also apply the equations to a specific mensurated impactor to show that a used impactor with some nozzles outside of the original manufacturing specifications can have the same aerodynamic performance as a new impactor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379616     DOI: 10.1089/jam.2005.18.396

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  5 in total

1.  Cascade impactor (CI) mensuration--an assessment of the accuracy and precision of commercially available optical measurement systems.

Authors:  Frank Chambers; Aziz Ali; Jolyon Mitchell; Christopher Shelton; Steve Nichols
Journal:  AAPS PharmSciTech       Date:  2010-03-23       Impact factor: 3.246

Review 2.  Particle size analysis in pharmaceutics: principles, methods and applications.

Authors:  Boris Y Shekunov; Pratibhash Chattopadhyay; Henry H Y Tong; Albert H L Chow
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

3.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

Review 4.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

5.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.